Hospital
Arh Mary Breckinridge Health Services, INC.
Arh Mary Breckinridge Health Services, INC. was paid $33.18M by Medicaid between Jan 2018 and Dec 2024, across 246 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoARH MARY BRECKINRIDGE HEALTH SERVICES, INC.
BARBOURVILLE, KY 40906
BARBOURVILLE, KY 40906
33aNPI1992176655assigned 10/07/2015
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$33.18M
24GClaims551,170
24DCodes billed246
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HARRIS, HOLLIE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 90,411 | $3.86M | |
| 2019 | 77,108 | $4.00M | |
| 2020 | 82,628 | $4.61M | |
| 2021 | 89,068 | $5.27M | |
| 2022 | 76,378 | $5.14M | |
| 2023 | 69,222 | $5.14M | |
| 2024incomplete | 66,355 | $5.16M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 10,826 | 9,067 | $5.73M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 10% | 4,350 | 3,878 | $3.34M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.3% | 21,735 | 18,895 | $2.43M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.6% | 3,655 | 2,848 | $2.18M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 4.0% | 1,738 | 1,474 | $1.34M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 2,623 | 2,183 | $953K |
| 80053 | Comprehensive metabolic panel | 2.5% | 44,728 | 27,324 | $839K |
| G0378 | Hospital observation service, per hour | 2.4% | 1,999 | 1,152 | $812K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 13,083 | 4,604 | $789K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 8,840 | 8,005 | $719K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 2.0% | 2,843 | 2,469 | $660K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.9% | 1,257 | 744 | $644K |
234 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 583 | $543K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 10,175 | $474K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 7,147 | $459K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 8,476 | $386K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 13,420 | $385K |
| 87631 | 1.2% | 4,483 | $385K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 7,050 | $350K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 32,909 | $350K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 633 | $332K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,319 | $322K |
| 36415 | Collection of venous blood by venipuncture | <1% | 103,514 | $300K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,659 | $278K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,204 | $266K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,048 | $238K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 202 | $198K |
| 80061 | Lipid panel | <1% | 6,262 | $196K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,202 | $193K |
| 84484 | <1% | 7,565 | $191K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,150 | $189K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 183 | $181K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,848 | $181K |
| 72100 | <1% | 1,833 | $161K | |
| 87040 | <1% | 4,002 | $159K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,732 | $146K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,598 | $142K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,869 | $140K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,505 | $137K |
| 83605 | <1% | 5,243 | $129K | |
| 83690 | <1% | 5,193 | $126K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,699 | $124K |
| 73630 | <1% | 1,621 | $123K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,916 | $120K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 193 | $112K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 133 | $107K |
| 80074 | <1% | 1,556 | $105K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,453 | $97K |
| 87522 | Neg quan hep c or qual rna | <1% | 2,383 | $96K |
| 73610 | <1% | 1,161 | $95K | |
| 73030 | <1% | 1,349 | $95K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,150 | $92K |
| 73562 | <1% | 1,370 | $91K | |
| 81001 | <1% | 9,755 | $89K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 503 | $88K |
| 87902 | <1% | 293 | $88K | |
| 82150 | <1% | 2,194 | $87K | |
| 82803 | <1% | 1,704 | $83K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,299 | $82K |
| 73130 | <1% | 970 | $80K | |
| 74018 | <1% | 987 | $77K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,494 | $76K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 322 | $72K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,895 | $72K |
| 82553 | <1% | 2,811 | $69K | |
| 83735 | <1% | 3,042 | $68K | |
| 85610 | <1% | 4,493 | $68K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,053 | $67K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 93 | $67K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 280 | $66K |
| 71250 | <1% | 143 | $65K | |
| 82607 | <1% | 2,876 | $62K | |
| 0100U | <1% | 840 | $58K | |
| 83516 | <1% | 767 | $58K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,234 | $57K |
| 72040 | <1% | 635 | $55K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 705 | $55K |
| 83880 | <1% | 2,047 | $55K | |
| 81025 | <1% | 2,732 | $55K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 83 | $54K |
| 83550 | <1% | 2,886 | $53K | |
| 72131 | <1% | 126 | $52K | |
| 85730 | <1% | 1,830 | $52K | |
| 93041 | <1% | 1,904 | $51K | |
| 87186 | <1% | 1,678 | $49K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,150 | $49K |
| 96376 | <1% | 1,100 | $47K | |
| 83540 | <1% | 2,396 | $47K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 908 | $47K |
| 82550 | <1% | 3,932 | $46K | |
| 99234 | <1% | 263 | $46K | |
| 76536 | <1% | 224 | $45K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,354 | $44K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,564 | $44K |
| 82172 | <1% | 1,216 | $42K | |
| 72072 | <1% | 331 | $40K | |
| 82570 | <1% | 1,488 | $40K | |
| 72110 | <1% | 309 | $40K | |
| 82247 | <1% | 1,621 | $38K | |
| 83883 | <1% | 779 | $37K | |
| 73110 | <1% | 442 | $36K | |
| 82728 | <1% | 1,120 | $36K | |
| 84145 | <1% | 837 | $35K | |
| 87070 | <1% | 1,392 | $34K | |
| 82977 | <1% | 1,537 | $34K | |
| 36600 | <1% | 1,979 | $34K | |
| 83010 | <1% | 1,292 | $32K | |
| 00731 | <1% | 76 | $31K | |
| 87077 | <1% | 2,362 | $30K | |
| 86038 | <1% | 761 | $28K | |
| 84439 | <1% | 1,066 | $27K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 718 | $25K |
| 84703 | <1% | 1,166 | $25K | |
| 96367 | <1% | 215 | $23K | |
| 00811 | <1% | 52 | $23K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,552 | $23K |
| 45384 | <1% | 26 | $22K | |
| 86140 | <1% | 1,765 | $22K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,103 | $20K |
| 81015 | <1% | 2,174 | $19K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,441 | $19K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 427 | $19K |
| 87076 | <1% | 2,385 | $19K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,583 | $18K |
| 84460 | <1% | 1,266 | $18K | |
| 83521 | <1% | 377 | $18K | |
| 87521 | Neg quan hep c or qual rna | <1% | 85 | $17K |
| 90714 | <1% | 509 | $16K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,650 | $16K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 293 | $14K |
| 96368 | <1% | 359 | $13K | |
| 85027 | <1% | 1,499 | $13K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 513 | $13K |
| 85652 | <1% | 1,330 | $13K | |
| 82248 | <1% | 565 | $12K | |
| 51702 | <1% | 295 | $12K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 875 | $11K |
| 82103 | <1% | 181 | $11K | |
| 87486 | <1% | 367 | $11K | |
| 87581 | <1% | 304 | $11K | |
| 86481 | <1% | 760 | $11K | |
| 82105 | <1% | 236 | $11K | |
| 82951 | <1% | 82 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 665 | $10K |
| 74022 | <1% | 55 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 745 | $10K |
| 84436 | <1% | 501 | $10K | |
| 73080 | <1% | 106 | $10K | |
| 73502 | <1% | 118 | $9K | |
| 82043 | <1% | 628 | $9K | |
| 86706 | <1% | 276 | $9K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 643 | $9K |
| 85378 | <1% | 590 | $7K | |
| 12001 | <1% | 67 | $7K | |
| 71271 | <1% | 13 | $7K | |
| 93971 | <1% | 42 | $6K | |
| 82652 | <1% | 254 | $6K | |
| 81003 | <1% | 965 | $6K | |
| 80320 | <1% | 245 | $6K | |
| 84481 | <1% | 80 | $6K | |
| 82274 | <1% | 174 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 625 | $6K |
| 0012A | <1% | 410 | $5K | |
| 81002 | <1% | 508 | $5K | |
| 80299 | <1% | 61 | $5K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 23 | $5K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,781 | $5K |
| 90715 | <1% | 89 | $5K | |
| 72050 | <1% | 48 | $4K | |
| 82270 | <1% | 266 | $4K | |
| 82140 | <1% | 154 | $4K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 154 | $4K |
| 80076 | <1% | 150 | $4K | |
| 86617 | <1% | 176 | $4K | |
| 0011A | <1% | 399 | $4K | |
| 85379 | <1% | 112 | $4K | |
| 82746 | <1% | 88 | $3K | |
| 72084 | <1% | 19 | $3K | |
| 73090 | <1% | 45 | $3K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 126 | $2K |
| 80164 | <1% | 689 | $2K | |
| 84479 | <1% | 155 | $2K | |
| 76770 | <1% | 18 | $2K | |
| 82565 | <1% | 157 | $2K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 158 | $2K |
| 76775 | <1% | 31 | $2K | |
| 84550 | <1% | 171 | $2K | |
| 73140 | <1% | 34 | $2K | |
| 29515 | <1% | 16 | $2K | |
| 86703 | <1% | 144 | $2K | |
| 93017 | <1% | 14 | $2K | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 267 | $2K |
| 84520 | <1% | 125 | $2K | |
| 93225 | <1% | 14 | $2K | |
| 83993 | <1% | 18 | $1K | |
| 80177 | <1% | 181 | $1K | |
| 87449 | <1% | 37 | $1K | |
| 84702 | <1% | 50 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,026 | $1K |
| 12002 | <1% | 12 | $1K | |
| 84478 | <1% | 147 | $1K | |
| 86255 | <1% | 115 | $1K | |
| 97162 | <1% | 32 | $1K | |
| 93226 | <1% | 14 | $1K | |
| 91200 | <1% | 17 | $1K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 83 | $1K |
| 82465 | <1% | 127 | $1K | |
| 71101 | <1% | 16 | $1K | |
| 84156 | <1% | 70 | $1K | |
| 0097U | <1% | 12 | $1K | |
| 84450 | <1% | 132 | $993.39 | |
| J3490 | Unclassified drugs | <1% | 181 | $990.65 |
| 82947 | <1% | 141 | $774.03 | |
| 80143 | <1% | 90 | $726.88 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 153 | $694.36 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 35 | $672.71 |
| 0064A | <1% | 68 | $588.12 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 85 | $563.84 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 46 | $553.47 |
| 80185 | <1% | 57 | $543.61 | |
| 87420 | <1% | 41 | $503.43 | |
| J0290 | Injection, ampicillin sodium, 500 mg | <1% | 25 | $471.60 |
| 84153 | <1% | 12 | $468.65 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 252 | $443.36 |
| 93975 | <1% | 13 | $411.08 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 186 | $396.18 |
| 86376 | <1% | 25 | $381.55 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 22 | $362.22 |
| 99499 | <1% | 13 | $276.68 | |
| 86308 | <1% | 16 | $238.31 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 108 | $205.67 |
| 80162 | <1% | 83 | $184.34 | |
| 84100 | <1% | 14 | $178.56 | |
| 83970 | <1% | 18 | $139.47 | |
| 86900 | <1% | 13 | $127.76 | |
| 86901 | <1% | 13 | $117.06 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 77 | $111.47 |
| A9270 | Non-covered item or service | <1% | 200 | $97.98 |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 27 | $95.28 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 16 | $86.62 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 107 | $81.12 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 30 | $72.51 |
| 82962 | <1% | 53 | $20.67 | |
| 97010 | <1% | 436 | $5.14 | |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 17 | $0.02 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, HOLLIE (PRESIDENT AND CEO)
Parent organizationAPPALACHIAN REGIONAL HELATHCARE, INC.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.